Background
malaria, chloroquine-resistant
MALARIA
Artemisinin-based combination therapy (ACT) is the current first-line treatment for uncomplicated Considering the emergence of clinical resistance to ACT, new treatment options are clearly required. Ferroquine and artefenomel are novel anti-malarial drug candidates and a combination of these two drugs has been proposed as a treatment for uncomplicated malaria. New anti-malarial therapeutics should be developed as fixed-dose combinations as this is expected to improve patient adherence and reduce the risk of parasite resistance developing to either drug, particularly if they have contrasting modes of action. When developing fixed-dose anti-malarial drug combinations, it is necessary to demonstrate the contribution of each component to overall efficacy and establish the safety and tolerability profile with co-administration [Artefenomel (also known as OZ439) is a synthetic peroxide, with a similar mechanism of action to artemisinin [Ferroquine is a 4-aminoquinoline analog, and a strong inhibitor of hemozoin formation, with high efficacy against chloroquine-resistant and ACT-resistant The efficacy and safety of ferroquine/artefenomel was evaluated in the ‘Ferroquine and Artefenomel in adults and children with FALCI was designed with only one dose level of artefenomel, and so there was a risk that the study would not be able to identify the contribution of artefenomel. Consequently, this parallel investigation was designed to specifically evaluate the artefenomel contribution to the efficacy of the combination in African adolescents and adults with uncomplicated 